# Wegovy (semaglutide) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/semaglutide

> The FDA approved Wegovy (semaglutide), sponsored by NOVO NORDISK A S (NVO), on March 19, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Wegovy (semaglutide) FDA approved?

Yes. The FDA approved Wegovy (semaglutide), sponsored by NOVO NORDISK A S (NVO), on March 19, 2026. SEC Form 8-K: "Bagsv&aelig;rd, Denmark, 19 March 2026 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term." [Calendar and source filings](https://sec-api.dev/pdufa/semaglutide)

Source: SEC Form 8-K, accession 0001171843-26-001813, https://www.sec.gov/Archives/edgar/data/353278/000117184326001813/f6k_031926.htm (retrieved 2026-11-12). Last confirmed 2026-03-20. Cite: https://sec-api.dev/pdufa/semaglutide#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Wegovy (semaglutide) |
| Codes |  |
| Sponsor | NOVO NORDISK A S (NVO) https://sec-api.dev/companies/nvo/catalysts |
| Indications | mash in adults with moderate to advanced liver fibrosis, moderate to advanced liver fibrosis, [obesity](https://sec-api.dev/indications/obesity), chronic heart failure, [Non-alcoholic Steatohepatitis](https://sec-api.dev/indications/non-alcoholic-steatohepatitis), Alcohol-related Liver Disease, [Chronic Kidney Disease](https://sec-api.dev/indications/chronic-kidney-disease), Overweight |
| Modality | peptide |
| FDA designations | accelerated, priority review, rmat |

## Timeline

### December 5, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209637 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171205, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22

### September 20, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213051 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20190920, review_priority PRIORITY; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22

### January 16, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213182 ORIG-1 (Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval): submission_status AP, submission_status_date 20200116, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product RYBELSUS (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213182%22

### January 16, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209637 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20200116, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22

### June 4, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20210604, review_priority PRIORITY; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22

### March 28, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209637 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20220328, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22

### December 23, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20221223, review_priority PRIORITY; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22

### July 21, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20230721, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22

### March 8, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20240308, review_priority PRIORITY; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22

### November 27, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20241127, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22

### Dec 2024: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-02-05, last confirmed 2025-02-05.
- SEC Form 8-K (accession 0001628280-25-003924): "In December 2024, Novo Nordisk initiated a phase 2 trial with a subcutaneous once-weekly dual GIP/GLP-1 agonist in approximately 450 people with chronic kidney disease, with or without type 2 diabetes and with overweight or obesity." https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm
- SEC Form 8-K (accession 0001628280-25-003924): "In December 2024, Novo Nordisk initiated a phase 1 trial with a once-weekly subcutaneous tri-agonist (Triple)." https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm
- SEC Form 8-K (accession 0001628280-25-003924): "In December 2024, Novo Nordisk initiated a phase 1 trial with once-weekly subcutaneous amylin 1213." https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm
- SEC Form 8-K (accession 0001628280-25-003924): "In December 2024, Novo Nordisk initiated a phase 1 trial with DCR-XDH using the GalXC-Plus™ platform." https://www.sec.gov/Archives/edgar/data/353278/000162828025003924/caq42024.htm

### December 9, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213051 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20241209, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22

### January 27, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-01-03, last confirmed 2025-02-13.
- SEC Form 10-Q (accession 0001437749-25-003734): "On January 27, 2025, the Company announced positive topline results from the Phase 2b QUALITY clinical study." https://www.sec.gov/Archives/edgar/data/863894/000143774925003734/veru20241231_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-000208): "Topline clinical results from the trial are expected in January of 2025." https://www.sec.gov/Archives/edgar/data/863894/000143774925000208/ex_761785.htm

### January 28, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209637 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209637%22

### May 28, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-02-13, last confirmed 2026-08-10.
- SEC Form 10-Q (accession 0001437749-26-026664): "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study portion during the 16 weeks of active weight loss that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." https://www.sec.gov/Archives/edgar/data/863894/000143774926026664/veru20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-016557): "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study portion during the 16 weeks of active weight loss that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." https://www.sec.gov/Archives/edgar/data/863894/000143774926016557/veru20260331_10q.htm
- SEC Form 10-Q (accession 0001437749-26-003725): "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study portion during the 16 weeks of active weight loss that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." https://www.sec.gov/Archives/edgar/data/863894/000143774926003725/veru20251231_10q.htm
- SEC Form 10-K (accession 0001437749-25-038089): "On May 28, 2025, we announced positive topline safety results for the Phase 2b QUALITY clinical study that showed the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone." https://www.sec.gov/Archives/edgar/data/863894/000143774925038089/veru20250930_10k.htm
- SEC Form 10-Q (accession 0001437749-25-003734): "The topline results of the separate blinded Phase 2b extension clinical study are expected in the second quarter of calendar 2025." https://www.sec.gov/Archives/edgar/data/863894/000143774925003734/veru20241231_10q.htm

### Jun 2025: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: obesity.
- First seen 2025-08-06, last confirmed 2025-08-06.
- SEC Form 8-K (accession 0001628280-25-038087): "In June 2025, Novo Nordisk initiated a phase 3b trial, REDEFINE 11, for CagriSema in people living with obesity." https://www.sec.gov/Archives/edgar/data/353278/000162828025038087/caq22025.htm
- SEC Form 8-K (accession 0001628280-25-038087): "As planned, in June 2025, Novo Nordisk initiated two phase 2 trials with CDR132L in patients with chronic heart failure." https://www.sec.gov/Archives/edgar/data/353278/000162828025038087/caq22025.htm

### August 15, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact. Indication: moderate to advanced liver fibrosis.
- First seen 2025-08-18, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20250815, review_priority PRIORITY; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22
- SEC Form 8-K (accession 0001171843-25-005454): "Bagsv&aelig;rd, Denmark, 15 August 2025 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet and increased physical activity." https://www.sec.gov/Archives/edgar/data/353278/000117184325005454/f6k_081525.htm
- SEC Form 8-K (accession 0000353278-25-000005): "In August 2025, Novo Nordisk announced that the US FDA approved a supplemental New Drug Application (sNDA) for an additional indication for Wegovy® (semaglutide 2.4 mg) for the treatment of MASH in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity." https://www.sec.gov/Archives/edgar/data/353278/000035327825000005/caq32025.htm

### September 9, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Type 2 Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06323161 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06323161

### September 15, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Early Alzheimer´s Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04777409 (A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-15 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT04777409

### September 24, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Chronic Kidney Disease; Type 2 Diabetes; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06131372 (A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06131372

### September 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-11-05, last confirmed 2025-11-05.
- SEC Form 8-K (accession 0000353278-25-000005): "•Within R&D, Novo Nordisk announced that the US FDA had approved an indication for Wegovy® for the treatment of MASH." https://www.sec.gov/Archives/edgar/data/353278/000035327825000005/caq32025.htm

### October 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Type 2 Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06323174 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06323174

### October 15, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05726227 (A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT05726227

### October 17, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213051 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20251017, review_priority STANDARD; sponsor_name NOVO; product OZEMPIC (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213051%22

### November 19, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Type 2 Diabetes Mellitus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06065540 (A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-19 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06065540

### November 21, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Alcohol-related Liver Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06409130 (Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-21 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06409130

### November 21, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22

### December 8, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06131437 (A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-08 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06131437

### December 22, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-02-03, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218316 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20251222, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218316%22
- SEC Form 8-K (accession 0000353278-26-000006): "Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved once-daily oral semaglutide" https://www.sec.gov/Archives/edgar/data/353278/000035327826000006/caq42025.htm

### March 4, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Type 2 Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06221969 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06221969

### March 19, 2026: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-03-20, last confirmed 2026-03-20.
- SEC Form 8-K (accession 0001171843-26-001813): "Bagsv&aelig;rd, Denmark, 19 March 2026 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term." https://www.sec.gov/Archives/edgar/data/353278/000117184326001813/f6k_031926.htm

### March 19, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215256 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20260319, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22

### April 22, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06388187 (A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-22 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06388187

### June 2, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06534411 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-02 (ACTUAL); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06534411

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Chronic Kidney Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06717698 (A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06717698

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Kidney Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06717698 (A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06717698

### Q1 2027: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-02-11, last confirmed 2026-05-13.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-220569): "—Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter calendar year 2027—" https://www.sec.gov/Archives/edgar/data/863894/000119312526220569/d114190dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-045527): "The Phase 2b PLATEAU clinical trial is expected to initiate this calendar quarter with interim analysis results anticipated Q1 calendar year 2027."" https://www.sec.gov/Archives/edgar/data/863894/000119312526045527/d218771dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-220569): "We are on track for presenting the results of the interim analysis which is expected in Q1 calendar year 2027," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc." https://www.sec.gov/Archives/edgar/data/863894/000119312526220569/d114190dex991.htm

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07639021 (A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07639021

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07639021 (A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07639021

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05669755 (REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT05669755

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cardiovascular Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05669755 (REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT05669755

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07415954 (A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-03 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07415954

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07415954 (A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-03 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07415954

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07668388

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07668388 (A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07668388

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-03-27, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03811561 (A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT03811561
- Press release filed with the SEC (EX-99) (accession 0001193125-26-220569): "Final topline clinical data is expected in the fourth quarter of calendar year 2027." https://www.sec.gov/Archives/edgar/data/863894/000119312526220569/d114190dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-384430): "Final topline clinical data is expected in the fourth quarter of calendar year 2027." https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/d543118dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-341187): "Final topline clinical data is expected in the fourth quarter of calendar year 2027." https://www.sec.gov/Archives/edgar/data/863894/000119312526341187/d123580dex991.htm
- SEC prospectus (424B) (accession 0001193125-26-161521): "We initiated the global Phase 3 clinical trials of KaiNETIC-2 and -3 in January 2026 and December 2025, respectively, and expect to report topline results in 2028." https://www.sec.gov/Archives/edgar/data/2096997/000119312526161521/d113532d424b4.htm
- SEC registration statement (S-1) (accession 0001193125-26-128952): "We initiated the global Phase 3 clinical trials of KaiNETIC-2 and -3 in January 2026 and December 2025, respectively, and expect to report topline results in 2028." https://www.sec.gov/Archives/edgar/data/2096997/000119312526128952/d113532ds1.htm

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03811561 (A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-07 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT03811561

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity; Type 2 Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07564414 (A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07564414

### Feb to May 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Overweight; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07770841 (Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-22 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07770841

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Overweight; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07770841 (Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-22 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07770841

### February 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity; Type 2 Diabetes.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07564414 (A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-23 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07564414

### June 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hypertension; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07919405 (A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07919405

### Jun to Sep 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hypertension; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07919405 (A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-06-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07919405

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Type 2 Diabetes.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07931573 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07931573

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07931599 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-24 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07931599

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Type 2 Diabetes.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07931573 (AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-04 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07931573

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Diabetes Mellitus, Type 2.
- First seen 2026-11-12T15:32:36.529Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07931599 (A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-07-24 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07931599

### Aug to Nov 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06780449 (A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-28 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06780449

### August 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06780449 (A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-28 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT06780449

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Overweight; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07668414 (A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07668414

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Overweight; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07668414 (A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07668414

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Obesity; Overweight; Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07400107 (AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07400107

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Obesity; Overweight; Diabetes Mellitus, Type 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07400107 (AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-19 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07400107

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-alcoholic Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04822181 (Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT04822181

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-alcoholic Steatohepatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04822181 (Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-25 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT04822181

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Overweight; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07253285 (A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-20 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07253285

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Overweight; Obesity.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07253285 (A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-20 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." https://clinicaltrials.gov/study/NCT07253285

## Same indication

- [ISEMBYLD (apitegromab)](https://sec-api.dev/pdufa/apitegromab) (SRRK)
- [Cagrilintide](https://sec-api.dev/pdufa/cagrilintide) (NVO)
- [CRB-913](https://sec-api.dev/pdufa/crb-913) (CRBP)
- [DA-1726](https://sec-api.dev/pdufa/da-1726) (MTVA)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)
- [Eloralintide](https://sec-api.dev/pdufa/eloralintide) (LLY)
- [Macupatide](https://sec-api.dev/pdufa/macupatide) (LLY)
- [NNC0487-0111](https://sec-api.dev/pdufa/nnc0487-0111) (NVO)
- [NNC0662-0419](https://sec-api.dev/pdufa/nnc0662-0419) (NVO)
- [Foundayo (orforglipron calcium)](https://sec-api.dev/pdufa/orforglipron) (LLY)
- [PF-08653945](https://sec-api.dev/pdufa/pf-08653945) (PFE)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [RT-114](https://sec-api.dev/pdufa/rt-114) (RANI)
- [RaniPill (RT-116)](https://sec-api.dev/pdufa/rt-116) (RANI)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [UBT251](https://sec-api.dev/pdufa/ubt251) (NVO)
- [VK2735](https://sec-api.dev/pdufa/vk2735) (VKTX)
- [WVE-007](https://sec-api.dev/pdufa/wve-007) (WVE)
- [Zenagamtide](https://sec-api.dev/pdufa/zenagamtide) (NVO)

Calendar months: [September 2026](https://sec-api.dev/fda-calendar/2026-09), [June 2027](https://sec-api.dev/fda-calendar/2027-06), [September 2027](https://sec-api.dev/fda-calendar/2027-09), [October 2027](https://sec-api.dev/fda-calendar/2027-10), [November 2027](https://sec-api.dev/fda-calendar/2027-11), [February 2028](https://sec-api.dev/fda-calendar/2028-02), [June 2028](https://sec-api.dev/fda-calendar/2028-06), [July 2028](https://sec-api.dev/fda-calendar/2028-07), [August 2028](https://sec-api.dev/fda-calendar/2028-08), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/semaglutide.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Wegovy (semaglutide) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/semaglutide

```bibtex
@misc{secapidev_pdufa_semaglutide_20261116,
  title        = {Wegovy (semaglutide) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/semaglutide}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_semaglutide_20261116","title":"Wegovy (semaglutide) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/semaglutide","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
